Bepo

Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation

By MedincellSeptember 20, 2020March 5th, 2024No Comments

Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation

September 20, 2020

Previous PostExpert Review Report: Medical Safety of Ivermectin
Next PostEffects of an injectable long-acting formulation of ivermectin on Onchocerca ochengi in zebu cattle

Better medicine for all

Website by ScreenUp